Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 12 g - injection, solution - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency; * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 3 g - injection, solution - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency; * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: sodium; octanoate - hypoproteinaemia in the acutely ill patient albapure? 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albapure? 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4 - 5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins resulting in hypovolaemic shock and circulatory failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii,von willebrand factor -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii,von willebrand factor -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: * primary immunodeficiency; * myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; * congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: * idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; * allogeneic bone marrow transplantation; * kawasaki disease; * guillain-barre syndrome (gbs).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, solution - excipient ingredients: sodium; octanoate - hypoproteinaemia in the acutely ill patient albumex 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock albumex 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 5% human albumin is preferred when available. burns extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure. initially (during the first 24 hours) there is an increased vascular permeability leading to loss of water and proteins into the extravascular compartment, and haemoconcentration. large volumes of crystalloid solutions should be infused to restore the constricted intravascular fluid space, and smaller amounts of albumex 20 are required to maintain adequate plasma volume and colloid osmotic pressure. adult respiratory distress syndrome the clinical syndrome is characterised by inadequate oxygenation secondary to pulmonary interstitial oedema, complicating shock and postoperative states resulting in a decreased central venous pressure, decreased plasma albumin concentration, rising blood pressure, reduced cardiac output, lowered pulse rate and a falling renal output. the acute condition can be controlled by diuretics and albumex 20 in amounts sufficient to maintain vital signs. in patients who have undergone abdominal surgery, the intravenous administration of albumin solution (20%) immediately after the operation has been shown to improve lung compliance and gaseous exchange. haemodialysis albumex 20 may be used to assist with the rapid removal of excess extravascular fluid and to maintain perfusion pressure. therapeutic plasma exchange therapeutic plasma exchange is a procedure in which approximately one plasma volume is exchanged with a colloid replacement solution. the choice of replacement fluid and its concentration are determined by the particular clinical situation and the frequency of the procedure. iso-oncotic albumin solution is the preferred replacement material. if the patient's serum albumin level is not maintained, concentrated albumin (20%) may be indicated. if exchange occurs less frequently than once a week, less concentrated colloids may be appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 12.5 g - injection, solution - excipient ingredients: sodium; chloride; octanoate - hypovolaemia/shock preservation of an adequate circulating blood volume should be the primary aim of therapy. the initial resuscitating fluid should not be a human blood product, but rather an alternative plasma volume expander should be used as first-line replacement. albumex 5 may, however, be the initial plasma expander of choice if shock is associated with significant hypoalbuminaemia (albumin concentration less than 25 g/litre), or if it is clinically desirable to avoid the infusion of large volumes of crystalloid solutions. albumex 5 may also be useful following initial resuscitation with crystalloid or synthetic colloid solutions in patients in whom extended support of the intravascular volume is required, such as seriously ill patients with multiple organ failure or the systemic capillary leak syndrome. cardiopulmonary bypass albumex 5 may be used for priming the pump for cardiopulmonary bypass surgery for patients with poor left ventricular function, and other complicating factors such as long bypass time, anaemia or repeat surgery. for post-operative hypovolaemia albumex 5 may be used if further colloid is required after a moderate amount of synthetic colloid (1-2l) has been given, or there is ongoing bleeding or anaemia, until cross-matched blood is available. plasma exchange albumex 5 is indicated as a replacement solution in plasma exchange procedures, particularly when the volume exchanged exceeds 20 ml/kg body weight. in patients with thrombotic thrombocytopenic purpura, fresh frozen plasma may be a preferred replacement.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 g/l - injection, intravenous infusion - excipient ingredients: maltose - intragam p is indicated for replacement igg therapy in: - primary immunodeficiency; - myeloma and chronic lymphocytic leukaemia with severe secondary - hypogammaglobulinaemia and recurrent infections; - congenital or acquired immune deficiency syndrome with recurrent infections. intragam p is indicated for immunomodulatory therapy in: - idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count; - allogeneic bone marrow transplantation; - kawasaki disease; - guillain-barr? syndrome (gbs).

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor x, quantity: 500 iu; factor ix, quantity: 500 iu; factor ii, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - prothrombinex?-vf is indicated in: ?treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required. ?treatment and prophylaxis of bleeding in patients with single or multiple congenital deficiency of factor ix, ii or x when purified specific coagulation factor product is not available.